Assessment of alteration in liver 18F–FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score

  • A. Michael PetersEmail author
  • Georgia Keramida
  • Deborah Pencharz
Letter to the Editor

Dear Sir,

We read with interest the article recently published in EJNMMI by Salomon et al. [1] that described a negative relationship between hepatic steatosis and SUV, and recommended the use of SULmax rather than SUVmax as the comparator in the Deauville scoring (DS) system because it minimises the influence of body mass index (BMI). They found, nevertheless, that it made little difference to DS whether SULmax or SUVmax was used. It is stated (but only in the Abstract) that in their scoring system, SULmax was applied to the lymphoma. Provided lymphoma and liver are compared either on the basis of SUV or SUL, body weight will cancel out and remove any influence of BMI on DS. It makes no sense to compare an SUL with an SUV, or vice versa, so normalising any tumour to liver removes the need to choose between SUL and SUV, provided whichever one is used is applied to both tissues.

In any event, in our view, the liver is just about the least appropriate tissue against which to normalise...


  1. 1.
    Salomon T, Nganoa1 C, Gac A-C, Fruchart C, Damaj G, Aide N, et al. Assessment of alteration in liver 18F–FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. Eur J Nucl Med Mol Imaging. 2017. Scholar
  2. 2.
    Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ulla Ruotsalainen U, Heikki Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med. 1993;34:1–6.Google Scholar
  3. 3.
    Hasselbalch SG, Knudsen GM, Videbaek C, Pinborg LH, Schmidt JF, Holm S, et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes. 1999;86:1915–21.CrossRefGoogle Scholar
  4. 4.
    Keramida G, Anagnostopoulos CD, Peters AM. The extent to which standardized uptake values reflect FDG phosphorylation in the liver and spleen as functions of time after injection of (18)F-fluorodeoxyglucose. Eur J Nucl Med Mol Imaging Res. 2017;7(1):13. Scholar
  5. 5.
    Bender D, Munk OL, Feng HQ, Keiding S. Metabolites of (18)F-FDG and 3-O-(11)C-methylglucose in pig liver. J Nucl Med. 2001;42:1673–8.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Keramida G, Potts J, Bush J, Dizdarevic S, Peters AM. Hepatic steatosis is associated with increased hepatic FDG uptake. Eur J Radiol. 2014;83:751–5.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Iozzo P, Geisler F, Oikonen V, Mäki M, Takala T, Solin O, et al. Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET study. J Nucl Med. 2003;44:682–9.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Green LA, Gambhir SS, Srinivasan A, Banerjee PK, Hoh CK, Cherry SR, et al. Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J Nucl Med. 1998;39:729–34.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Namba H, Nakagawa K, Iyo M, Fukushi K. Irie T. A simple method for measuring glucose utilization of insulin-sensitive tissues by using the brain as a reference. Eur J Nucl Med. 1994;21:228–31.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • A. Michael Peters
    • 1
    Email author
  • Georgia Keramida
    • 2
  • Deborah Pencharz
    • 1
  1. 1.Brighton and Sussex Hospitals NHS TrustBrightonUK
  2. 2.Royal Brompton and Harefield Foundation TrustLondonUK

Personalised recommendations